Literature DB >> 22143783

Antigen-specific induced Foxp3+ regulatory T cells are generated following CD40/CD154 blockade.

Ivana R Ferrer1, Maylene E Wagener, Minqing Song, Allan D Kirk, Christian P Larsen, Mandy L Ford.   

Abstract

Blockade of the CD40/CD154 pathway potently attenuates T-cell responses in models of autoimmunity, inflammation, and transplantation. Indeed, CD40 pathway blockade remains one of the most powerful methods of prolonging graft survival in models of transplantation. But despite this effectiveness, the cellular and molecular mechanisms underlying the protective effects of CD40 pathway blockade are incompletely understood. Furthermore, the relative contributions of deletion, anergy, and regulation have not been measured in a model in which donor-reactive CD4(+) and CD8(+) T-cell responses can be assessed simultaneously. To investigate the impact of CD40/CD154 pathway blockade on graft-specific T-cell responses, a transgenic mouse model was used in which recipients containing ovalbumin-specific CD4(+) and CD8(+) TCR transgenic T cells were grafted with skin expressing ovalbumin in the presence or absence of anti-CD154 and donor-specific transfusion. The results indicated that CD154 blockade altered the kinetics of donor-reactive CD8(+) T-cell expansion, delaying differentiation into IFN-γ(+) TNF(+) multifunctional cytokine producers. The eventual differentiation of cytokine-producing effectors in tolerant animals coincided with the emergence of an antigen-specific CD4(+) CD25(hi) Foxp3(+) T-cell population, which did not arise from endogenous natural T(reg) but rather were peripherally generated from naïve Foxp3(-) precursors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22143783      PMCID: PMC3251074          DOI: 10.1073/pnas.1105500108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  45 in total

1.  CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells.

Authors:  V Henn; J R Slupsky; M Gräfe; I Anagnostopoulos; R Förster; G Müller-Berghaus; R A Kroczek
Journal:  Nature       Date:  1998-02-05       Impact factor: 49.962

2.  CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment.

Authors:  X X Zheng; T G Markees; W W Hancock; Y Li; D L Greiner; X C Li; J P Mordes; M H Sayegh; A A Rossini; T B Strom
Journal:  J Immunol       Date:  1999-04-15       Impact factor: 5.422

3.  Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates.

Authors:  A D Kirk; L C Burkly; D S Batty; R E Baumgartner; J D Berning; K Buchanan; J H Fechner; R L Germond; R L Kampen; N B Patterson; S J Swanson; D K Tadaki; C N TenHoor; L White; S J Knechtle; D M Harlan
Journal:  Nat Med       Date:  1999-06       Impact factor: 53.440

4.  Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection.

Authors:  W W Hancock; M H Sayegh; X G Zheng; R Peach; P S Linsley; L A Turka
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

5.  A pivotal role for CD40-mediated IL-6 production by dendritic cells during IL-17 induction in vivo.

Authors:  Georgia Perona-Wright; Stephen J Jenkins; Richard A O'Connor; Dimitrios Zienkiewicz; Henry J McSorley; Rick M Maizels; Stephen M Anderton; Andrew S MacDonald
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

6.  Prolonged survival of rat islet and skin xenografts in mice treated with donor splenocytes and anti-CD154 monoclonal antibody.

Authors:  E J Gordon; T G Markees; N E Phillips; R J Noelle; L D Shultz; J P Mordes; A A Rossini; D L Greiner
Journal:  Diabetes       Date:  1998-08       Impact factor: 9.461

7.  RNAi-mediated silencing of CD40 prevents leukocyte adhesion on CD154-activated endothelial cells.

Authors:  Raquel Pluvinet; Jordi Pétriz; Joan Torras; Inmaculada Herrero-Fresneda; Josep M Cruzado; Josep M Grinyó; Josep M Aran
Journal:  Blood       Date:  2004-08-17       Impact factor: 22.113

8.  Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon-gamma, and CTLA4.

Authors:  T G Markees; N E Phillips; E J Gordon; R J Noelle; L D Shultz; J P Mordes; D L Greiner; A A Rossini
Journal:  J Clin Invest       Date:  1998-06-01       Impact factor: 14.808

9.  CD40-gp39 interactions play a critical role during allograft rejection. Suppression of allograft rejection by blockade of the CD40-gp39 pathway.

Authors:  C P Larsen; D Z Alexander; D Hollenbaugh; E T Elwood; S C Ritchie; A Aruffo; R Hendrix; T C Pearson
Journal:  Transplantation       Date:  1996-01-15       Impact factor: 4.939

10.  Cutting edge: long-lived CD8 memory and protective immunity in the absence of CD40 expression on CD8 T cells.

Authors:  Joseph C Sun; Michael J Bevan
Journal:  J Immunol       Date:  2004-03-15       Impact factor: 5.422

View more
  42 in total

1.  Latent virus infection upregulates CD40 expression facilitating enhanced autoimmunity in a model of multiple sclerosis.

Authors:  Costanza Casiraghi; Ana Citlali Márquez; Iryna Shanina; Marc Steven Horwitz
Journal:  Sci Rep       Date:  2015-09-10       Impact factor: 4.379

Review 2.  Novel Immunomodulatory Approaches for Porcine Islet Xenotransplantation.

Authors:  So-Hee Hong; Hyun-Je Kim; Seong-Jun Kang; Chung-Gyu Park
Journal:  Curr Diab Rep       Date:  2021-01-12       Impact factor: 4.810

Review 3.  Challenges and opportunities in targeting the CD28/CTLA-4 pathway in transplantation and autoimmunity.

Authors:  Rebecca L Crepeau; Mandy L Ford
Journal:  Expert Opin Biol Ther       Date:  2017-05-30       Impact factor: 4.388

Review 4.  New insights into T-cell cosignaling in allograft rejection and survival.

Authors:  Scott M Krummey; Mandy L Ford
Journal:  Curr Opin Organ Transplant       Date:  2015-02       Impact factor: 2.640

5.  Permanent acceptance of mouse cardiac allografts with CD40 siRNA to induce regulatory myeloid cells by use of a novel polysaccharide siRNA delivery system.

Authors:  Q Zhang; N Ichimaru; S Higuchi; S Cai; J Hou; M Fujino; N Nonomura; M Kobayashi; H Ando; A Uno; K Sakurai; S Mochizuki; Y Adachi; N Ohno; H Zou; J Xu; X-K Li; S Takahara
Journal:  Gene Ther       Date:  2015-01-08       Impact factor: 5.250

6.  Preemptive Tolerogenic Delivery of Donor Antigens for Permanent Allogeneic Islet Graft Protection.

Authors:  Shusen Wang; Xiaomin Zhang; Lei Zhang; Jane Bryant; Taba Kheradmand; Bernhard J Hering; Stephen D Miller; Xunrong Luo
Journal:  Cell Transplant       Date:  2014-04-22       Impact factor: 4.064

Review 7.  Impact of infection on transplantation tolerance.

Authors:  Shuangjin Yu; Chang Su; Xunrong Luo
Journal:  Immunol Rev       Date:  2019-09-19       Impact factor: 12.988

8.  Fc-Silent Anti-CD154 Domain Antibody Effectively Prevents Nonhuman Primate Renal Allograft Rejection.

Authors:  S C Kim; W Wakwe; L B Higginbotham; D V Mathews; C P Breeden; A C Stephenson; J Jenkins; E Strobert; K Price; L Price; R Kuhn; H Wang; A Yamniuk; S Suchard; A B Farris; T C Pearson; C P Larsen; M L Ford; A Suri; S Nadler; A B Adams
Journal:  Am J Transplant       Date:  2017-02-25       Impact factor: 8.086

Review 9.  Novel insights into anti-CD40/CD154 immunotherapy in transplant tolerance.

Authors:  David F Pinelli; Mandy L Ford
Journal:  Immunotherapy       Date:  2015       Impact factor: 4.196

Review 10.  T Cell Cosignaling Molecules in Transplantation.

Authors:  Mandy L Ford
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.